0.00 (0.00%) 1d

Related posts

This week’s new 52-week highs and lows … (Jan 23-29)This week’s new 52-week lows… (Nov 28-Dec 04)

Good company. In some interesting spaces in terms of hormonal stuff. They are on the search for a Viagra for women. The numbers into 2016 are looking pretty good. He wants to see one or 2 more quarters, but if they keep doing things the way they are, it is a name he would be interested in. Wouldn’t be surprised if he ends up owning it in 2016.

Consumer Products

Working on an application of testosterone. In the current method you have to be extremely careful using it. This is a nasal application. If successful, it will be beneficial. There seems to be a debate of testosterone supplementing for men, which seems to have died down a little. There will be a reasonable opportunity to get the results over the next 6 months. Lost $0.27 last year, which is improving to a loss of $0.11 this year. If they are successful, the stock could be quite significant. Very speculative.

Consumer Products

(Market Call Minute.) Wouldn’t own this. Too risky and there are a lot of financing issues. High risk.

Consumer Products

Have an ingenious nasal application system. Still waiting for the next stages of approval, particularly on the application for men. Application for women is behind that.

Consumer Products

In the drug delivery systems business. Good management. Into phase 3. Part of the problem recently is that one of the big investors has been selling, which has spooked some people.

Consumer Products
New drug delivery for more testosterone. Got a lot of attention because they are working on the female Viagra. It is a concept stock because they are in trials. If it works out it could be a huge win. But there are no revenue or earnings at this point so there is a lot of ability for downside. A licensing deal would be the catalyst.
Consumer Products
Showing 1 to 6 of 6 entries
  • «
  • 1
  • »

Acerus Pharmaceuticals(ASP-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Acerus Pharmaceuticals is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Acerus Pharmaceuticals(ASP-T) Frequently Asked Questions

What is Acerus Pharmaceuticals stock symbol?

Acerus Pharmaceuticals is a Canadian stock, trading under the symbol ASP-T on the Toronto Stock Exchange (ASP-CT). It is usually referred to as TSX:ASP or ASP-T

Is Acerus Pharmaceuticals a buy or a sell?

In the last year, there was no coverage of Acerus Pharmaceuticals published on Stockchase.

Is Acerus Pharmaceuticals a good investment or a top pick?

Acerus Pharmaceuticals was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Acerus Pharmaceuticals.

Why is Acerus Pharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Acerus Pharmaceuticals worth watching?

0 stock analysts on Stockchase covered Acerus Pharmaceuticals In the last year. It is a trending stock that is worth watching.

What is Acerus Pharmaceuticals stock price?

On 2023-01-26, Acerus Pharmaceuticals (ASP-T) stock closed at a price of $0.36.